Zobrazeno 1 - 10
of 16
pro vyhledávání: '"SCG Lima"'
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S279- (2023)
Objectives: Acute Myeloid Leukemia (AML) is a complex and heterogeneous disease characterized by the blockage of blood cell maturation, leading to uncontrolled proliferation of immature malignant cells. Based on cytogenetic characteristics, AML can b
Externí odkaz:
https://doaj.org/article/f1e79d0a0f294b22971d32e759f365fb
Autor:
SCG Lima, R Rossetti, AU Quadros, KS Esteves, IP Furtado, DMC Fantacini, RM Silveira, DT Covas, LEB Souza
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S536-S537 (2023)
Allogeneic Chimeric Antigen Receptor (CAR) T cell therapy represents a promising approach to overcome the accessibility limitations of conventional autologous treatment. Some advantages of such allogeneic therapy include the availability of an off-th
Externí odkaz:
https://doaj.org/article/283d458406fb404c973eb783bd75ac37
Autor:
IP Furtado, RM Silveira, R Rossetti, DMC Fantacini, SCG Lima, L Tsyrenov, H Shiku, LEB Souza, DT Covas
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S539- (2023)
The treatment of solid tumors with CAR-T cells is challenging due to the complex tumor microenvironment that impairs infiltration and persistence of injected cells. Thus, enhancing persistence and resistance to exhaustion of CAR-T cells is desirable
Externí odkaz:
https://doaj.org/article/4338a707b7564228a987ea7f9526f459
Autor:
R Rossetti, SCG Lima, DMC Fantacini, JV Carvalho, IP Furtado, RM Silveira, L Tsyrenov, H Shiku, LEB Souza, DT Covas
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S541-S542 (2023)
Despite the remarkable success in the use of T cells expressing Chimeric Antigen Receptors (CAR) for hematologic malignances, their application to solid tumors, which represents the majority of neoplasms, remains challenging. However, T lymphocytes e
Externí odkaz:
https://doaj.org/article/6947851cc4da4c29b391223624c59dab
Autor:
DMC Fantacini, SCG Lima, R Rossetti, IP Furtado, RM Silveira, L Tsyrenov, H Shiku, DT Covas, LEB Souza
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S552- (2023)
Adoptive therapy using Chimeric Antigen Receptor T-cell (CAR-T) technology has emerged as a groundbreaking immunotherapeutic approach for treating various hematological malignancies. Among the diverse CAR-T targets, CD19, a B-cell surface marker, has
Externí odkaz:
https://doaj.org/article/2725cbb49d1f4b6ab45d030b16c7529e
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S258-S259 (2021)
Introduction: Chimeric antigen receptor (CAR)-T cell therapy has a remarkable clinical success. However, its autologous nature reduces accessibility to the therapy. Thus, one of the next frontiers in the field is to develop an allogeneic, ‘off-the-
Externí odkaz:
https://doaj.org/article/ba0f6496d3744f24923aa9254d7ad0e9
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S267- (2021)
Introdução: O tratamento com linfócitos T expressando receptores quiméricos de antígeno (CAR) ou receptores de células T (TCR) artificiais tem resultado em taxas de remissão impressionantes para algumas neoplasias hematológicas. Porém, a efi
Externí odkaz:
https://doaj.org/article/7ea4b15d7e784865a8a7f03fa69e4e4a
Publikováno v:
Hematology, Transfusion and Cell Therapy. 44:S316-S317
Publikováno v:
Hematology, Transfusion and Cell Therapy. 44:S300-S301
Publikováno v:
Hematology, Transfusion and Cell Therapy. 44:S314